SCHEMBL6316151

SCHEMBL6316151

Nc1onc(-c2ccccn2)c1C(=O)Nc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 10/20 0.56
CA2 P00918 10/20 0.56
CA4 P22748 10/20 0.56
CA7 P43166 10/20 0.56
PRKCI P41743 1/20 0.47
CYP2C9 P11712 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PTGS2 P35354 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP1A2 P05177 1/20 0.45
ATR Q13535 1/20 0.45
LMNA P02545 1/20 0.44
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
F2 P00734 1/20 0.43
F10 P00742 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316431 0.90 CA1 (0.52) CA1CA2CA4CA7CYP2C9
SCHEMBL6315950 0.84 KDM4E (0.43) CA1CA2CA4CA7SMN1; SMN2
SCHEMBL6323194 0.84 CA2 (0.53) CA1CA2CA4CA7SMN1; SMN2
SCHEMBL6316253 0.82 RAB9A (0.51) CA1CA2CA4CA7SMN1; SMN2
SCHEMBL6319053 0.81 HPGDS (0.54) SMN1; SMN2MAPK1CYP1A2LMNANPC1
SCHEMBL6315249 0.81 ALDH1A1 (0.47) CA1CA2CA4CA7LMNA
SCHEMBL6316243 0.81 RAB9A (0.52) SMN1; SMN2MAPK1LMNANPC1RAB9A
SCHEMBL6316191 0.81 CYP2C9 (0.53) CYP2C9SMN1; SMN2CYP3A4CYP1A2LMNA
SCHEMBL6318141 0.81 RET (0.47) CYP1A2LMNAGAA
SCHEMBL6316835 0.80 KDR (0.56) SMN1; SMN2LMNANPC1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 CA1 2406/4885CA2 2764/4885CA4 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.